NASDAQ
06.02.26 | 21:57
1,090 US-Dollar
-0,91 % -0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EVOGENE Aktie jetzt für 0€ handeln | |||||
| Mi | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.01. | Evogene Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 07.01. | Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders | 114 | PR Newswire | Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design... ► Artikel lesen | |
| 30.12.25 | Evogene appoints Dr. Olga Nissan as VP of business development | 3 | Investing.com | ||
| 30.12.25 | Evogene ernennt Dr. Olga Nissan zur Vice President für Geschäftsentwicklung | 4 | Investing.com Deutsch | ||
| 30.12.25 | Evogene Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.11.25 | Evogene übertrifft Gewinnerwartungen nach Restrukturierung trotz Umsatzrückgangs | 2 | Investing.com Deutsch | ||
| 20.11.25 | Evogene: EPS übertrifft Schätzungen um 0,12 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 20.11.25 | Evogene GAAP EPS of -$0.31 beats by $0.10, revenue of $0.31M misses by $0.34M | 2 | Seeking Alpha | ||
| 20.11.25 | Evogene Reports Third Quarter 2025 Financial Results | 113 | PR Newswire | Conference call and webcast: today, November 20, 2025, 9:00 AM ET
Financial Highlights:
During the first nine months ending September 30, 2025, Evogene advanced... ► Artikel lesen | |
| 20.11.25 | Evogene Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.11.25 | Evogene Q3 2025 Earnings Preview | 1 | Seeking Alpha | ||
| 19.11.25 | What's Next: Evogene's Earnings Preview | 1 | Benzinga.com | ||
| 30.09.25 | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09.25 | Evogene Ltd. - 6-K, Report of foreign issuer | 10 | SEC Filings | ||
| 19.08.25 | Evogene Q2 2025: Kostensenkungen federn verfehlte Umsatz- und Gewinnziele ab | 3 | Investing.com Deutsch | ||
| 19.08.25 | Evogene GAAP EPS of -$0.85 misses by $0.22, revenue of $0.88M misses by $0.05M | 1 | Seeking Alpha | ||
| 19.08.25 | Evogene Reports Second Quarter 2025 Financial Results | 179 | PR Newswire | Conference call and webcast: today, August 19, 2025, 9:00 am ET
Financial Highlights:
The financial results for the first half of 2025 of Lavie Bio, a subsidiary... ► Artikel lesen | |
| 18.08.25 | Evogene Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.08.25 | Preview: Evogene's Earnings | 1 | Benzinga.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| STRYKER | 302,10 | -0,33 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders... ► Artikel lesen | |
| BIOGEN | 164,25 | +3,79 % | Ihre wichtigsten Termine: Frische Zahlen von Philip Morris, Under Armour, Toyota, Biogen, Societe Generale | © Foto: Hiro Komae/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 662,80 | -0,27 % | REGENERON PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,410 | +0,71 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,339 | +1,14 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| INFLARX | 0,730 | -2,54 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,320 | -0,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EDITAS MEDICINE | 1,536 | +0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,320 | +0,28 % | Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts |
Das Unternehmen EVOGENE LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,91 % bei einem Aktienkurs von 1,090 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOGENE LTD finden Sie auf Wallstreet Online.